我們已在上線！進一步了解

Cardio Diagnostics

CDIO

市值 US$500萬

1.69 USD

-0.07

3.98%

收盤時已更新 10月16日下午4:00 EDT

1天

-3.98%

5天

-11.05%

1個月

-15.5%

3個月

0%

6個月

-13.78%

今年迄今

-40.49%

1年

-60.97%

5年

-99.43%

10年

-99.43%

關於： Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.

員工： 17

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 0%

中性 100%

負面 0%

Cardio Diagnostics Holdings, Inc. (CDIO) Shareholder/Analyst Call Prepared Remarks Transcript

Cardio Diagnostics Holdings, Inc. (CDIO) Shareholder/Analyst Call Prepared Remarks Transcript

Cardio Diagnostics Holdings, Inc. (CDIO) Shareholder/Analyst Call Prepared Remarks Transcript

Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has released a new edition of the company's rural health report: The State of Rural Hospitals and Cardiovascular Care.

Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges

Cardio Diagnostics Holdings, Inc. (CDIO) Discusses Precision Molecular Advances and AI for Cardiovascular Disease Detection and Strategic Growth Initiatives Prepared Remarks Transcript

Cardio Diagnostics Holdings, Inc. (CDIO) Discusses Precision Molecular Advances and AI for Cardiovascular Disease Detection and Strategic Growth Initiatives Prepared Remarks Transcript

Cardio Diagnostics Holdings, Inc. (CDIO) Discusses Precision Molecular Advances and AI for Cardiovascular Disease Detection and Strategic Growth Initiatives Prepared Remarks Transcript

Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics launched its in-house, high-complexity CLIA-certified laboratory in Iowa City, Iowa.

Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City

Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. will host an investor conference call on Thursday, August 20, 2026, at 3 p.m. Central Time.

Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026

Atlas Healthcare Physicians to Cover Cardio Diagnostics' Precision Cardiovascular Medicine Tests Across Its Network

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced that Atlas Healthcare Physicians (AHP) will cover Cardio Diagnostics' tests, Epi+Gen CHD™ and PrecisionCHD™.

Atlas Healthcare Physicians to Cover Cardio Diagnostics' Precision Cardiovascular Medicine Tests Across Its Network

Cardio Diagnostics Holdings, Inc. to Showcase Precision Cardiovascular Solutions at Four National Benefits Conferences in June

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will exhibit at four upcoming national benefits conferences.

Cardio Diagnostics Holdings, Inc. to Showcase Precision Cardiovascular Solutions at Four National Benefits Conferences in June

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Meesha Dogan, CEO of Cardio Diagnostics Holdings Inc.

AUSTIN, Texas, May 20, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Meesha Dogan, CEO of Cardio Diagnostics Holdings Inc.

CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, February 19, 2026

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will host an investor conference call on Thursday, February 19, 2026, at 3 p.m. Central Time.

CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, February 19, 2026

Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time.

Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

查看新聞排名

價格圖表採用Lightweight Charts™實作